MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-09-2025
Tilray DSO Ratio 2011-2026 | TLRY
Annual DSO Ratio Tilray
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.8 | 53 | 41.4 | 13.4 | 133 | 148 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 148 | 13.4 | 73.6 |
Quarterly DSO Ratio Tilray
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 49.8 | - | - | 44.9 | 46.9 | - | 46.3 | 43.3 | 43.4 | - | 52.7 | 59.5 | 57.7 | 29.2 | 54 | 53.5 | 50.1 | 24.6 | 42.8 | 19 | 20 | -2.23 K | -1.02 K | 1.3 | 1.2 | 1.33 | 34.1 | 97.1 | 150 | 155 | 102 | 17.5 | 16.6 | 8.98 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 155 | -2.23 K | -64.3 |
DSO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Zynerba Pharmaceuticals
ZYNE
|
14.6 K | - | - | $ 55.5 M |  USA |
 |
Alimera Sciences
ALIM
|
122 | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
71.7 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
117 | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
62.7 | $ 1.2 | 1.27 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
16.5 | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
203 | $ 2.68 | -0.56 % | $ 1.42 B | Canada |
 |
Agile Therapeutics
AGRX
|
63.1 | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
80.1 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
100 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
65.5 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
79.9 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
45.7 | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
71.3 | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
60.9 | $ 13.92 | 5.86 % | $ 713 M | USA |
 |
OrganiGram Holdings
OGI
|
93 | $ 1.69 | 0.9 % | $ 402 M | Canada |
 |
Athenex
ATNX
|
89.9 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
49.9 | $ 21.48 | -0.12 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
53.6 | $ 5.72 | -3.3 % | $ 355 M | USA |
 |
Harrow Health
HROW
|
22.3 | $ 50.79 | -5.07 % | $ 1.66 B | USA |
 |
Jupiter Wellness
JUPW
|
134 | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
29.7 | $ 1.38 | 9.13 % | $ 24.1 M |  China |
 |
Sonoma Pharmaceuticals
SNOA
|
65.5 | $ 3.8 | - | $ 4.72 M | USA |
 |
Bausch Health Companies
BHC
|
78.9 | $ 7.9 | 3.41 % | $ 2.88 B | Canada |
 |
Lannett Company
LCI
|
83.1 | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
3.46 | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
375 | $ 5.14 | 8.9 % | $ 72.3 M | USA |
 |
Organogenesis Holdings
ORGO
|
72.6 | $ 4.32 | -0.92 % | $ 569 M | USA |
 |
Pacira BioSciences
PCRX
|
50.3 | $ 26.13 | 3.24 % | $ 1.21 B | USA |
 |
Aurora Cannabis
ACB
|
99.8 | $ 4.23 | -0.25 % | $ 86.3 M | Canada |
 |
Rockwell Medical
RMTI
|
37.5 | $ 0.95 | 2.85 % | $ 22.2 M | USA |
 |
PetIQ
PETQ
|
43.1 | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
57.7 | $ 14.7 | -0.47 % | $ 2.02 B | USA |
 |
ProPhase Labs
PRPH
|
111 | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
91.5 | $ 2.34 | 0.43 % | $ 316 M | USA |
 |
Radius Health
RDUS
|
16.1 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
62.7 | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
11.3 | $ 1.11 | -3.91 % | $ 4.79 M | USA |
 |
OptiNose
OPTN
|
138 | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
112 | $ 9.35 | -1.86 % | $ 664 M | USA |
 |
PLx Pharma
PLXP
|
14.1 | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
106 | $ 0.64 | -0.12 % | $ 30.6 M | USA |
 |
TherapeuticsMD
TXMD
|
2.3 K | $ 2.0 | -2.0 % | $ 20.9 M | USA |
 |
Zomedica Corp.
ZOM
|
13 | - | -0.21 % | $ 98 M | USA |